Drugs / anti-CD123 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03672851 | Apr → Jul 2019 | acute myeloid leukemia | Second Affiliated Hospital of Xi'an Jiaotong University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD123 CAR-T cells | “anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia” NCT03672851 ↗ |
| Modality | Cell therapy | “anti-CD123 CAR-T cells” NCT03672851 ↗ |
| Route | Intravenous | “autologous anti-CD123 CAR T cells IV over 20 minutes” NCT03672851 ↗ |